期刊文献+

肾功能不全痛风患者临床药疗方案的研究进展 被引量:6

原文传递
导出
摘要 目的:为肾功能不全痛风患者的治疗药物选择提供参考。方法:对伴肾功能不全的痛风患者在急性发作期及缓解期治疗痛风的药物选择进行综述。结果与结论:肾功能不全是很多痛风患者常见的并发症之一。在痛风急性发作期,肾功能不全的患者与肾功能正常的患者在治疗目标方面虽然没有差异,但在治疗药物的选择及某些药物的剂量使用方面却需要谨慎。对于肾功能不全的痛风患者,药物应用应遵循个体化用药原则,并根据肾功能情况选择合适的治疗药物及剂量。注意痛风药物用药剂量、药物禁忌证,加强监测患者的药品不良反应,同时避免应用使血尿酸升高的药物。
出处 《中国药房》 CAS CSCD 2013年第2期171-173,共3页 China Pharmacy
  • 相关文献

参考文献18

  • 1Niel E, Shermann JM.Colchicine today[J].Joint Bone Spi-2006,73(6):672.
  • 2Terkeltaub RA.Colchicine update : 2008[J].Sewm ArthritisRheum, 2009,38(6) :411.
  • 3Terkeltaub RA. Clinical practice.Gout[J]. N Engl J Med,2003,349(17):1 647.
  • 4Gaffo AL Saag KG. Management of hyperuricemia andgout in CKD[J]. American Journal of Kidney Diseases,2008,52(5):994.
  • 5Cocco G,Chu DC, Pandolfl S.Colchicine in clinical med-icine.A guide for intemists[J]._Ewro/?ea? Journal of Inter-nal Medicine,2010,21(6) :503.
  • 6Jordan KM, Cameron JS,Snaith M,ef al. British societyfor rheumatology and british health professionals in rheu-matology guideline for the management of gout[J]. Rheu-matology2007,46(8) : 1 372.
  • 7El-Zawawy H,Mandell BF.Managing gout: How is it dif-ferent in patients with chronic kidney disease?[J].C/eve-land Clinic Journal of Medicine, 2010,77( 12) : 919.
  • 8Schumacher HR, Boice JA,Daikh DI,et al.Randomised do-uble blind trial of etoricoxib and indometacin in treatment ofacute gouty arthritis[J].SM/,2002,324(7 352) : 1 488.
  • 9Clive DM. Renal transplant-associated hyperuricemia andgout[J]. J Am Soc Nephrol, 2000,11(5) :974.
  • 10Man CY, Cheung IT, Cameron PA, et al.Comparison oforal prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acutegoutlike arthritis: a double-blind, randomized, controlledtrial[J].Ann Emerg Med, 2007,49 (5) :670.

二级参考文献41

  • 1Takano Y, Hase - Aoki K, Horiuchi H, et al. Selectivity of febuxostat, a novel non - purine inhibitor of xan- thine oxidase/xanthine dehydrogenase[j ]. Life Sci, 2005, 76(16) : 1 835.
  • 2Horiuchi H,Ota M, Nishimura SI, et al .Allopurinol induces renal toxicity by impairing pyrimidine metabolism in mice[J].Life Sci ,2000,66(21):2 051.
  • 3Khosravan R, Grabowski BA, Wu JT, et al . Pharmacokineties, pharmacodynamlcs and safety of febuxostar, a non- purine selective inhibitor of xanthine oxidase, in a close escalation study in healthy subjects[J ]. Clin Pharmacoki net, 2006,45(8) : 821.
  • 4Becker MA, Schumacher HRJ, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout[J ] .N Engl J IVied, 2005, 353(23):2 450.
  • 5Khosravan R, Grabowski BA, Mayer MD, et al .The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase[J ] .J Clin Pharmacol, 2006,46(1) : 88.
  • 6Hoshide S,Takahashi Y, Ishikawa T, et al .PK/PD and safety of a single dose of TMX- 67 (Febuxostat) in subiects with mild and moderate renal impairment[J] . Nucleosides Nucleotides Nucleic Acids, 2004, 23(8-- 9) : 1 117.
  • 7Mayer MD, Khosravan R, Vernillet L, et al. Pharmacokinetics and pharmacodynamics of febuxostat, a new non- purine selective inhibitor of xanthine oxidase in subjects with renal impairment[J ] .Am J Ther ,2005, 12(1):22.
  • 8Khosravan R,Grabowski B,Wu JT, et al .Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects[J] .Br J Clin Pharmacol, 2008, 65 (3) : 355.
  • 9Mukoyoshi M, Nishimura S, Hoshide S, et al. In vitro drug - drug interaction studies with febuxostat, a novel non - purine selective inhibitor of xanthine oxidase: plasma protein binding, identification of metabolic en-zymes and cytochrome P450 inhibition[J] . Xenobiotica, 2008,38(5) : 496.
  • 10Khosravan R, Wu JT, Joseph - Ridge N, et al. Pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs[J ] .J Clin Pharmacol, 2006, 46(8) : 855.

共引文献16

同被引文献65

引证文献6

二级引证文献98

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部